VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KNSA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KNSAKiniksa Pharmaceuticals International, plc
$94.23$7.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksKNSAFinancials

Kiniksa Pharmaceuticals International, plc (KNSA) Income Statement

10Y historyFree accessUpdated daily

Revenue reached $286.0M in 2026Q3 with 58.1% year-over-year growth and 19.0% operating margin, yet gross margin remains anchored near 53.3% by the Regeneron profit-share structure versus a 60.9% level seen in 2024Q2.

Income StatementBalance SheetCash FlowRatios

KNSA Income Statement

Annual statement

KNSA Income Statement

Kiniksa Pharmaceuticals International, plc (KNSA) annual income statement — 10-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Sales/Revenue945.96M677.56M423.24M270.26M220.18M38.54M00000
Revenue Growth %58.19%60.09%56.61%22.74%471.24%------
Cost of Goods Sold432.7M307.41M60.91M56.52M22.89M9.1M3.81M3.28M286K28K22K
COGS % of Revenue-45.37%14.39%20.91%10.4%23.61%-----
Gross Profit513.27M370.15M362.33M213.74M197.28M29.44M-3.81M-3.28M-286K-28K-22K
Gross Margin %54.26%54.63%85.61%79.09%89.6%76.39%-----
Gross Profit Growth %-2.16%69.52%8.34%570.03%873.82%-16.04%-1046.5%-921.43%-27.27%-
Operating Expenses382.8M292.93M407.94M238.93M187.51M186.08M153.56M166.68M108.16M65.4M24M
OpEx % of Revenue-43.23%96.39%88.41%85.16%482.77%-----
Selling, General & Admin247.15M196.27M168.01M129.43M97.95M85.95M43.92M33.75M21.56M9.04M6.56M
SG&A % of Revenue-28.97%39.7%47.89%44.49%222.99%-----
Research & Development135.8M96.85M111.62M76.1M65.49M99.3M109.64M132.93M86.6M56.36M17.44M
R&D % of Revenue-14.29%26.37%28.16%29.74%257.62%-----
Other Operating Expenses00128.31M33.41M24.07M835K00000
Operating Income130.47M77.22M-45.62M-25.2M9.77M-156.64M-157.36M-169.96M-108.16M-65.4M-24M
Operating Margin %13.79%11.4%-10.78%-9.32%4.44%-406.38%-----
Operating Income Growth %-269.28%-81.04%-357.81%106.24%0.46%7.41%-57.14%-65.38%-172.48%-
EBITDA132.36M78.78M-43.92M-22.86M12.18M-154.28M-154.96M-167.9M-107.87M-65.37M-23.98M
EBITDA Margin %13.99%11.63%-10.38%-8.46%5.53%-400.27%-----
EBITDA Growth %233.9%279.36%-92.17%-287.72%107.89%0.44%7.71%-55.64%-65.02%-172.61%-
D&A (Non-Cash Add-back)1.9M1.55M1.7M2.34M2.4M2.35M2.4M2.07M286K28K22K
EBIT142.2M88.87M-36.15M-16.65M11.03M-156.54M-156.23M-163.91M-108.16M-65.4M-24M
Net Interest Income10.08M11.65M9.46M8.54M1.25M97K1.13M6.05M000
Interest Income10.08M11.65M9.46M8.54M1.25M97K1.13M6.05M4.72M529K65K
Interest Expense00000000000
Other Income/Expense15.69M11.65M9.46M8.54M1.25M97K1.13M6.05M4.72M529K65K
Pretax Income146.15M88.87M-36.15M-16.65M11.03M-156.54M-156.23M-163.91M-103.44M-64.87M-23.94M
Pretax Margin %15.45%13.12%-8.54%-6.16%5.01%-406.13%-----
Income Tax36.58M29.86M7.04M-30.74M-172.34M1.39M5.15M-2.05M-214K2K36K
Effective Tax Rate %25.03%33.6%-19.48%184.58%-1563.01%-0.88%-3.3%1.25%0.21%-0%-0.15%
Net Income109.57M59.01M-43.19M14.08M183.36M-157.92M-161.38M-161.87M-103.23M-64.87M-23.97M
Net Margin %11.58%8.71%-10.21%5.21%83.28%-409.72%-----
Net Income Growth %205.05%236.61%-406.68%-92.32%216.11%2.14%0.3%-56.81%-59.12%-170.61%-
Net Income (Continuing)109.57M59.01M-43.19M14.08M183.36M-157.92M-161.38M-161.87M-103.23M-64.87M-23.97M
Discontinued Operations00000000000
Minority Interest00000000000
EPS (Diluted)1.290.75-0.600.202.60-2.30-2.61-2.99-3.49-2.00-0.74
EPS Growth %191.11%225%-400%-92.31%213.04%11.88%12.71%14.33%-74.5%-170.27%-
EPS (Basic)-0.80-0.600.202.64-2.30-2.61-2.99-3.49-2.00-0.74
Diluted Shares Outstanding84.92M78.98M71.42M71.92M70.42M68.58M61.84M54.05M29.55M32.47M32.47M
Basic Shares Outstanding78.19M74.2M71.42M70.06M69.38M68.58M61.84M54.05M29.55M32.47M32.47M
Dividend Payout Ratio-----------

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Single-product concentration and margin ceiling

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

ARCALYST Drives Exceptional Top-Line Acceleration

Kiniksa's quarterly revenue surged from $108.6M in 2024Q2 to $286.0M in 2026Q3, representing approximately 163% cumulative growth over ten quarters, according to reported financial statements, driven primarily by accelerating ARCALYST new patient starts in the recurrent pericarditis market.

Revenue growth has remained remarkably consistent at 44-72% year-over-year across every reported quarter, suggesting durable market penetration rather than a one-time launch spike. The sequential revenue progression from $202.1M (2025Q4) to $286.0M (2026Q3) appears to reflect both new prescriber adoption and potentially extended duration of therapy, which would increase lifetime patient value. Management's decision to raise 2026 guidance to $980-$995M following Q2 results implies they see no near-term plateau, though the reliance on a single approved product for essentially all commercial revenue concentrates trajectory risk around payer reauthorization dynamics and any future competitive entry into the RP indication.

Gross Margin Ceiling Set by Profit-Share Structure

Kiniksa's gross margin has stabilized in the 53-55% range since a 46.0% trough in 2024Q4, reflecting the structural impact of the Regeneron profit-sharing arrangement, as reported in SEC filings, which permanently caps margins well below the 80-90% observed at asset-owning orphan drug peers.

The 46.0% gross margin in 2024Q4 appears anomalous relative to the surrounding quarters and may reflect a one-time gross-to-net adjustment or cost allocation shift, though the specific driver is not discernible from the data alone. The subsequent stabilization around 53-55% suggests the current margin profile is the structural steady state, which has meaningful valuation implications: Kiniksa's gross margin is roughly half that of Ardelyx (89.5%) and Arcus (96.0%), reflecting the economic reality that a significant portion of ARCALYST economics flows to Regeneron. This margin ceiling means incremental revenue growth translates to profit at a lower rate than typical biotech peers, and any future gross-to-net deterioration from shifting payer mix could compress margins further within an already constrained band.

Commercial Scale-Out Delivers Operating Leverage

Over the ten-quarter period, Kiniksa's SG&A grew approximately 54% from $42.4M to $65.4M while revenue expanded 163%, resulting in operating margin improvement from -0.1% to 19.0%, as reported in recent financial statements, suggesting meaningful commercial infrastructure operating leverage.

The operating leverage profile is striking: SG&A as a percentage of revenue has compressed from 39.0% in 2024Q2 to 22.9% in 2026Q3, indicating the existing commercial infrastructure is absorbing higher volumes without proportional cost increases. This suggests the ARCALYST sales force and patient support model were built with substantial forward capacity, and current growth is leveraging an already-deployed infrastructure. However, operating margin has exhibited quarter-to-quarter volatility (ranging from 9.8% to 19.0% in profitable quarters), largely driven by lumpy R&D spend that swung from $18.8M to $40.9M. Investors should note that operating leverage is currently being partially offset by R&D investment, and the sustainability of the 19.0% operating margin in 2026Q3 depends partly on R&D timing rather than purely commercial efficiency.

SBC Ramp and Tax Effects Cloud EPS Quality

Stock-based compensation accelerated to $13.1M in 2026Q3 from $3.9M in 2025Q4, representing roughly 4.6% of revenue, and EPS growth figures have been distorted by base effects from loss-making prior-year periods, according to Kiniksa's quarterly filings, warranting scrutiny of underlying cash earnings quality.

The dramatic swing in reported EPS growth rates (from 2.5% in 2025Q4 to 143.5% in 2026Q3) is largely an artifact of comparing against depressed or negative prior-year bases rather than reflecting fundamental acceleration, and should be interpreted cautiously. The step-up in SBC from $3.9M in 2025Q4 to $13.1M in 2026Q3—a nearly threefold sequential increase—suggests either a large equity grant vesting event or a structural change in compensation policy, which economically dilutes shareholders even if it does not affect non-GAAP metrics. Net margin has also exhibited volatility (from 6.2% in 2025Q1 to 16.6% in 2026Q3), likely reflecting non-operating items and tax rate variability typical of a company transitioning from loss-making to consistently profitable status. The convergence of net income ($47.3M) below operating income ($54.2M) in 2026Q3 appears normal but the magnitude of the gap warrants monitoring for recurring non-operating charges.

Single-Asset Dependency and Structural Margin Cap

Despite impressive 55-58% recent quarterly revenue growth, Kiniksa remains almost entirely dependent on ARCALYST with a gross margin capped near 55% by the Regeneron profit share, and pipeline candidate KPL-404 faces intensifying CD40 pathway competition from large-cap peers, presenting meaningful downside scenarios if either pillar falters.

The most credible bear case centers on three converging risks: first, any erosion in ARCALYST's competitive position—whether from payer-driven substitution to off-label Kineret or future direct competitors—would disproportionately impact a company where product sales represent nearly all revenue. Second, the Regeneron profit share means Kiniksa captures roughly half the economic value of its lead product, structurally limiting cash generation relative to what a fully-owned asset would produce, which constrains the company's ability to self-fund pipeline development at scale. Third, the KPL-404 program, while providing long-term optionality, is entering a CD40/CD154 competitive landscape that has become significantly more crowded, and the R&D spending volatility observed in the data (ranging from $18.8M to $40.9M quarterly) suggests development timelines and cost profiles remain uncertain. The 2026Q3 operating margin of 19.0% represents a peak that may prove difficult to sustain if R&D normalizes upward or if SG&A must re-accelerate to defend market share.

2025Q1 Marks Sustained Profitability Transition

The 2025Q1 quarter represents the critical inflection point when Kiniksa first achieved positive operating income ($13.3M) and net income ($8.5M), transitioning from sustained losses, and the company has generated consistent profitability in every subsequent quarter, as reported in quarterly financial statements.

Prior to 2025Q1, Kiniksa posted operating losses in every reported quarter (2024Q2 through 2024Q4), with the most severe loss of $19.3M in 2024Q4 coinciding with the lowest gross margin (46.0%) and elevated R&D spend ($35.1M). The inflection appears driven by the crossing of a revenue threshold—approximately $137.8M quarterly—at which the fixed commercial infrastructure becomes self-sustaining. What makes this inflection durable rather than transitory is that operating income has expanded in tandem with revenue growth, reaching $54.2M by 2026Q3, rather than oscillating around breakeven. This pattern suggests the company has passed a structural profitability threshold, though the narrow gross margin band means the durability of this inflection remains tightly coupled to continued top-line momentum in the RP market.

KNSA — Frequently Asked Questions

Quick answers to the most common questions about buying KNSA stock.

What was Kiniksa Pharmaceuticals International, plc's (KNSA) revenue in 2025?

For fiscal year 2025, Kiniksa Pharmaceuticals International, plc (KNSA) reported total revenue of $677.6M.

Is Kiniksa Pharmaceuticals International, plc (KNSA) profitable?

Kiniksa Pharmaceuticals International, plc (KNSA) is profitable, generating $59.0M in net income for the fiscal year ending 2025 with a net profit margin of 8.7%.

What is Kiniksa Pharmaceuticals International, plc's operating profit margin?

Kiniksa Pharmaceuticals International, plc (KNSA) reported an operating income of $77.2M, resulting in an operating profit margin of 11.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Kiniksa Pharmaceuticals International, plc's gross profit and gross margin?

Kiniksa Pharmaceuticals International, plc (KNSA) generated $370.1M in gross profit for the year, representing a gross profit margin of 54.6%. This demonstrates the company's core pricing power and production efficiency.